首页> 美国卫生研究院文献>Infection and Immunity >Oral vaccination of monkeys with an invasive Escherichia coli K-12 hybrid expressing Shigella flexneri 2a somatic antigen.
【2h】

Oral vaccination of monkeys with an invasive Escherichia coli K-12 hybrid expressing Shigella flexneri 2a somatic antigen.

机译:用表达弗氏志贺氏菌2a体抗原的侵袭性大肠杆菌K-12杂种对猴子进行口服疫苗接种。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A living oral vaccine, designed to protect against Shigella flexneri 2a infections, was constructed by using Escherichia coli K-12 as a carrier strain. The hybrid strain, designated EC104, contained both chromosomal and plasmid genes from S. flexneri donor strains. In addition to expressing the S. flexneri 2a somatic antigen, it had inherited the property of epithelial-cell invasion. After the oral administration to rhesus monkeys, EC104 was isolated from the feces for up to 3 days, but by day 4 all stool cultures were negative. The serum antibody response against S. flexneri 2a somatic antigen was variable, but the vaccine conferred significant protection against an oral challenge with virulent S. flexneri 2a.
机译:通过使用大肠杆菌K-12作为载体菌株,构建了一种旨在预防弗氏志贺氏菌2a感染的口服活疫苗。命名为EC104的杂种菌株包含弗氏链球菌供体菌株的染色体和质粒基因。除了表达弗氏链球菌2a体抗原外,它还继承了上皮细胞侵袭的特性。对恒河猴口服给药后,从粪便中分离EC104长达3天,但到第4天,所有粪便培养均为阴性。针对弗氏志贺氏菌2a体抗原的血清抗体反应是可变的,但该疫苗针对强效弗氏志贺氏菌2a的口服攻击具有显着的保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号